主动脉分叉覆膜支架重建技术(CERAB)治疗主髂动脉闭塞性疾病的长期结局
单中心连续纳入160例择期行CERAB的主髂动脉闭塞性疾病患者,5年一期、一期辅助和二期通畅率分别为77.5%、88.1%和95.0%,免于临床驱动靶病变血运重建率84.4%。既往主髂动脉干预是丧失一期通畅率的最强预测因素(OR=5.36,95%CI 1.30-22.07,p=0.020)。
要点
- CERAB术后5年一期、一期辅助、二期通畅率分别为77.5%、88.1%、95.0%。
- 既往主髂动脉干预者丧失一期通畅率的OR=5.36(95%CI 1.30-22.07,p=0.020)。
- 5年随访时97.9%患者Rutherford分级改善,免于大截肢率100%。
核心结论
- CERAB技术长期结局良好,尤其在初次治疗病例中;既往主髂动脉闭塞性疾病治疗过的患者再干预更多,监测可能应更密集。
研究设计与样本
- 单中心连续纳入择期行CERAB治疗主髂动脉闭塞性疾病的患者160例(男性79例),收集基线、手术及6周、6个月、12个月及此后每年随访数据。
主要发现
- 121例(75.6%)因间歇性跛行治疗,133例(83.1%)为TASC-II D级病变,技术成功率95.6%,30天死亡率1.3%。
- 5年一期、一期辅助、二期通畅率分别为77.5%、88.1%、95.0%,免于临床驱动靶病变血运重建率为84.4%。
- 丧失一期通畅率的最强预测因素为既往主髂动脉干预(OR=5.36,95%CI 1.30-22.07,p=0.020)。
- 既往未治疗主髂动脉段者5年一期、一期辅助、二期通畅率分别为85.1%、94.4%、96.9%。
- 5年随访时97.9%患者Rutherford分级改善,免于大截肢率100%。
临床怎么用
- 作者认为CERAB是广泛主髂动脉闭塞性疾病的有效治疗选择。
- 作者建议对目标区域既往治疗过的患者可考虑其他治疗选择,或需更密集的随访监测。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) reconstruction is an endovascular technique, developed to reconstruct the aortic bifurcation in the most optimal anatomical and physiological manner. Short-term data were promising, but long-term data are still lacking. The objective was to report the long-term outcomes of CERAB for extensive aorto-iliac occlusive disease and to identify predictors for loss of primary patency. METHODS: Consecutive electively treated patients with CERAB for aorto-iliac occlusive disease in a single hospital were identified and analyzed. Baseline and procedural data and follow-up were collected at 6-weeks, 6 months, 12 months, and annually thereafter. Technical success, procedural, and 30-day complications were evaluated, as well as overall survival. Patency and freedom from target lesion revascularization rates were analyzed using Kaplan Meier curves. Uni- and multivariate analysis were performed to identify possible predictors of failure. RESULTS: One hundred and sixty patients were included (79 male). Indication for treatment was intermittent claudication for 121 patients (75.6%) and 133 patients (83.1%) had a TASC-II D lesion. Technical success was obtained in 95.6% of patients and the 30-day mortality rate was 1.3%. The 5-year primary, primary-assisted, and secondary patency rates were 77.5%, 88.1%, and 95.0%, respectively, with a freedom-from clinically driven target lesion revascularization (CD-TLR) rate of 84.4%. The strongest predictor of loss of primary patency of CERAB was a previous aorto-iliac intervention (odds ratio [OR]=5.36 (95% confidence interval [CI]: 1.30; 22.07), p=0.020). In patients not previously treated in the aorto-iliac tract, 5-year primary, primary assisted, and secondary patency rates were 85.1%, 94.4%, and 96.9%, respectively. At 5-year follow-up, an improved Rutherford was found in 97.9% of patients and the freedom from major amputation rate was 100%. CONCLUSION: The CERAB technique is related to good long-term outcomes, particularly in primary cases. In patients that had prior treatment for aorto-iliac occlusive disease, there were more reinterventions and therefore surveillance should likely be more intense. CLINICAL IMPACT: The Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) reconstruction was designed to improve outcomes of endovascular treatment of extensive aorto-iliac occlusive disease. At 5-year follow-up clinical improvement was found in 97.9% of patients without major amputations. The 5-year overall primary, primary-assisted, and secondary patency rates were 77.5%, 88.1%, and 95.0%, respectively, with a freedom-from clinically driven target lesion revascularization rate of 84.4%. Significantly better patency rates were observed for patients that were never treated before in the target area. The data implicate that CERAB are a valid treatment option for patients with extensive aorto-iliac occlusive disease. For patients previously treated in the target area, other treatment options might be considered, or more intensive follow-up surveillance is warranted.
引用
- Rouwenhorst KB, Abdelbaqy OMA, van der Veen D, et al. Long-Term Outcomes of the Covered Endovascular Reconstruction of the Aortic Bifurcation (CERAB) Technique in Patients With Aorto-Iliac Occlusive Disease. J Endovasc Ther. 2023. PMID: 37114939. doi:10.1177/15266028231166539
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。